Safety and therapeutic potential of M2-macrophages in XXXX treatment.

@entity1 @entity650 @entity410 @entity64 @entity548 @entity63 @entity7 @entity1356 @entity310 @entity540 @entity379 @entity3646 @entity687 @entity688
UNASSIGNED: Our objective was to evaluate the safety and clinical efficacy of autologous M2 macrophage transplantation in non-acute @entity64 @entity1 . We also evaluated whether the intrathecal administration of macrophages influences the production of cytokines by peripheral blood cells, and whether the levels of cytokines correlate with @entity64 severity and responsiveness to celltherapy. For this, thirteen @entity1 (12 males and one female with median 63 years) diagnosed with @entity63 (n=10) or @entity548 (n=3) @entity64 have been subjected to cell transplantation therapy (study group). On average 21.9 x 10(6) of autologous M2 macrophages were injected via intrathecal introduction. Thirteen matched case-control @entity64 @entity1 who did not receive cell therapy formed the control group. We did not observe any serious adverse events, i.e. intrahospital mortality, neurological worsening and @entity410 , related to the cell injection. One @entity1 in the study group and two @entity1 in the control group died during the 6-mo follow-up period due to the recurrent @entity64 . In the study group the NIHSS score decreased from 11 to 6 (p=0.007) in 6 mo after the therapy, whereas the @entity1 in the control group showed a less pronounced neurological improvement (the NIHSS score decreased from 11 to 8; p=0.07). The obvious positive response (the improvement of the NIHSS score >= 3) in the study group was observed in 75% versus 18% in the control group (pFET=0.03). M2-cell introduction did not significantly affect the production of various cytokines. Nevertheless, pretreated levels of @entity687 , @entity688 and @entity3646 correlated with @entity64 severity. Moreover, responder @entity1 were differed from non-responders by lower spontaneous production of @entity688 , @entity540 , PDGF, @entity7 and higher stimulation indexes of @entity1356 , @entity310 , @entity379 and @entity650 . These findings suggest that the intrathecal administration of autologous M2 cells in @entity64 @entity1 is safe and leads to a better neurological recovery, which could be mediated through the immunomodulatory activity of M2 macrophages.
